查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929524

全球澱粉樣蛋白抗治療市場（依治療類型、適應症、給藥途徑、作用機制、患者年齡層和最終用戶分類）預測（2026-2032年）

Anti-amyloid Therapy Market by Therapy Type, Indication, Route Of Administration, Mechanism Of Action, Patient Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗澱粉樣蛋白治療市場規模將達到 73.9 億美元，到 2026 年將成長至 79.9 億美元，複合年成長率為 13.92%，到 2032 年將達到 184.2 億美元。

關鍵市場統計數據
基準年 2025 73.9億美元
預計年份：2026年 79.9億美元
預測年份 2032 184.2億美元
複合年成長率 (%) 13.92%

目前抗澱粉樣蛋白治療環境的框架，其中科學進步、監管變化和支付方決策共同決定臨床和商業性結果。

抗澱粉樣蛋白治療領域已進入關鍵階段，科學檢驗、監管政策的重新解讀以及支付者的決策正在交匯融合，重塑臨床路徑和商業策略。生物製藥的進步正在拓展治療工具箱，而不斷發展的診斷能力和患者識別策略正在最佳化緩解疾病干預的目標族群。同時，包括研究機構、生命科學公司、醫療保健系統和支付方在內的相關人員正在重新調整工作重點，以平衡臨床效益、安全性以及長期價值創造。

科學進步、監管調整和支付方框架的演變如何共同重塑臨床開發、商業化和病患就醫途徑？

近期科學突破、監管機構的訊號以及支付方的實驗性措施正在共同推動抗澱粉樣蛋白療法領域的變革。免疫療法和標靶胜肽療法已從概念驗證邁向更廣泛的臨床應用，迫使監管機構重新評估證據要件和有條件核准途徑。儘管這些政策調整降低了部分市場進入門檻，但也加強了對真實世界療效和安全性監測的審查，並迫使申辦方設計超越隨機對照試驗的綜合證據產生策略。

評估2025年美國關稅將如何重塑抗澱粉樣蛋白治療生態系統的供應鏈韌性、製造經濟和支付方動態。

2025年美國關稅將改變全球藥品供應鏈的經濟和物流結構，進而為抗澱粉樣蛋白治療領域的相關人員帶來更多挑戰。這些關稅將增加活性藥物原料藥、生物製藥製劑原料、特殊試劑以及某些成品在國際生產網路中的成本，促使製造商重新評估其籌資策略和庫存管理政策。為此，許多機構正在加速供應商多元化、投資近岸生產以及建立策略性庫存緩衝機制，以降低關稅波動帶來的風險，並確保臨床試驗用藥和商業分銷的持續供應。

基於深度細分的洞察，揭示了治療層級、適應症、給藥途徑、醫療環境、分銷管道、作用機制和年齡層的策略影響

觀點市場進行細分，可以揭示相關人員可以利用的、實現臨床和商業性差異化的微妙路徑。依治療方法類型分類，競爭格局包括單株抗體、胜肽和小分子藥物，其中單株抗體可進一步細分為嵌合體、全人源型和人源化型。每類藥物都有其獨特的生產需求、免疫抗原性特徵和監管預期，這些都會影響研發進度和商業化策略。依適應症分類，輕度至中度阿茲海默症和重度阿茲海默症的臨床策略有所不同，其中輕度至中度阿茲海默症可進一步細分為輕度和中度。這些適應症的細微差別決定了試驗終點、病患入組標準和核准後證據要求。

美洲、歐洲、中東和非洲以及亞太地區的區域戰略重點將影響監管方式、准入途徑和商業化策略。

區域趨勢將對監管路徑、報銷環境和商業部署策略產生決定性影響，對美洲、歐洲、中東和非洲以及亞太地區的影響各不相同。在美洲，監管先例和支付方談判機制往往傾向於強力的證據包和基於價值的合約試點項目，促使製造商與主要醫療系統合作，投資於真實世界證據和分階段部​​署策略。同時，該地區部分地區先進的診斷基礎設施正在加速患者識別，但仍存在就醫難的問題，需要補充患者外展服務和中心輻射式分銷模式來覆蓋都市區。

生物製藥創新者、生物技術新創參與企業、合約研發生產機構 (CDMO) 和診斷合作夥伴之間的競爭與合作策略，塑造了產品差異化和商業成功。

活躍於抗澱粉樣蛋白領域的主要企業透過專業化的研發管線、策略合作以及對上游診斷和下游患者支持的投資來實現差異化。大型生物製藥公司專注於抗體工程和可擴展生技藥品生產的平台能力，而規模較小的生物技術公司則往往致力於開發獨特的作用機制和創新的遞送平台，以創造差異化的臨床價值。合約研發生產機構（CDMO）在實現複雜生技藥品和胜肽類藥物的可擴展生產方面發揮著至關重要的作用，其產能限制和擴張對申辦方的策略和上市時間有著重大影響。

為領導者提供切實可行的策略建議，以協調研發、生產韌性、診斷夥伴關係、定價創新和以病人為中心的醫療服務取得計畫。

產業領導者應協調一致地採取一系列策略行動，以在抗澱粉樣蛋白領域獲得臨床、監管和商業性優勢。首先，為使研發計畫與下游證據要求保持一致，應將真實世界資料收集和病患報告結果納入臨床實驗和核准後監測，同時解決監管機構和支付方提出的問題。其次，應實現生產和採購基地多元化，以降低地緣政治風險和關稅干擾的影響。考慮將關鍵零件的生產外包到附近地區，並協商靈活的供應商協議，以確保供應的連續性。第三，應投資於診斷夥伴關係和臨床醫生培訓，以加速準確識別患者和合理用藥，這將有助於與支付者溝通並推動藥物的普及應用。

為確保研究結果可靠且可操作，我們採用了穩健的混合調查方法，結合了相關人員訪談、二手證據綜合、三角驗證和檢驗。

本研究採用混合方法，結合質性相關人員觀點和系統性證據綜合，以獲得嚴謹且可操作的見解。主要研究包括對臨床研究人員、醫療系統領導者、監管事務專業人員、支付方代表和生產專家進行深度訪談，以收集關於臨床終點、試驗可行性、報銷考量和供應鏈限制的第一手資訊。為補充這些訪談，次要證據綜合分析了同行評審文獻、監管指導文件、臨床試驗註冊庫和公司披露資訊，以梳理科學進展、安全性考慮和監管態度。

綜合結論強調了在將抗澱粉樣蛋白治療創新轉化為持續的患者可及性方面取得的進展、面臨的多重挑戰以及所需的策略重點。

總之，抗澱粉樣蛋白治療領域兼具科學前景與系統複雜性，需要整合實證策略。單株抗體、胜肽和小分子藥物等治療創新為影響疾病生物學提供了多種途徑，但每種方法都面臨獨特的生產、臨床和醫療保險報銷挑戰。法規環境和支付環境也在同步發展，對真實世界證據和可驗證的功能性結果的要求日益提高，因此，積極主動地制定核准後研究計劃和創造性的合約模式至關重要。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 澱粉樣蛋白抗療法市場（依治療方法）

  • 單株抗體
    • 嵌合體單株抗體
    • 完全人體單株抗體
    • 人源化單株抗體
  • 胜肽
  • 低分子化合物

9. 依適應症分類的澱粉樣蛋白抗治療市場

  • 輕度至中度阿茲海默症
    • 輕度阿茲海默症
    • 中度阿茲海默症
  • 重度阿茲海默症

10. 依給藥途徑分類的澱粉樣蛋白抗治療市場

  • 靜脈注射
  • 口服
  • 皮下注射

11. 依作用機轉分類的澱粉樣蛋白抗治療市場

  • 抑制BETA-澱粉樣蛋白聚集
  • BETA-澱粉樣蛋白清除
  • 抑制BETA-澱粉樣蛋白的產生
  • 神經炎症調節

12. 依患者年齡層分類的澱粉樣蛋白抗治療市場

  • 65-74歲
  • 75歲或以上
  • 65歲以下

13. 依最終用戶分類的澱粉樣蛋白抗治療市場

  • 居家醫療
  • 醫院
    • 私立醫院
    • 公立醫院
  • 專科診所
  • 遠端醫療服務

14. 各地區澱粉樣蛋白抗療法市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

15. 澱粉樣蛋白抗療法市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國澱粉樣蛋白抗療法市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國澱粉樣蛋白抗療法市場

第18章：中國的澱粉樣蛋白抗治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-0A38069517F4

The Anti-amyloid Therapy Market was valued at USD 7.39 billion in 2025 and is projected to grow to USD 7.99 billion in 2026, with a CAGR of 13.92%, reaching USD 18.42 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.39 billion
Estimated Year [2026] USD 7.99 billion
Forecast Year [2032] USD 18.42 billion
CAGR (%) 13.92%

Framing the current anti-amyloid therapeutic environment where scientific advances, regulatory shifts, and payer decisions jointly determine clinical and commercial outcomes

The anti-amyloid therapeutic space has entered a decisive phase, where scientific validation, regulatory reinterpretation, and payer adjudication converge to reshape clinical trajectories and commercial strategies. Advances in biologics, peptide chemistry, and small-molecule approaches have expanded the therapeutic toolkit, while evolving diagnostic capabilities and patient identification strategies refine the target population for disease-modifying interventions. Concurrently, stakeholders across research institutions, life sciences companies, health systems, and payers are recalibrating priorities to balance clinical benefit, safety profiles, and long-term value generation.

This introduction positions the reader to appreciate how technological innovation intersects with regulatory precedent and payer behavior to influence adoption curves, clinical pathways, and supply chain design. It underscores the urgency for cross-functional alignment: clinical development teams must coordinate with manufacturing and market access stakeholders to translate laboratory advances into accessible therapies. By framing the current environment in terms of scientific momentum and systemic friction points, the following sections illuminate where strategic interventions can materially affect outcomes for patients and organizations alike.

How scientific advances, regulatory recalibration, and evolving payer frameworks are jointly redefining clinical development, commercialization, and patient access

Recent scientific breakthroughs, regulatory signals, and payer experiments are collectively producing transformative shifts across the anti-amyloid therapy landscape. Immunotherapies and targeted peptides have progressed from proof-of-concept into broader clinical application, prompting regulators to refine evidentiary expectations and conditional pathways. These policy adaptations have lowered certain barriers to market entry but also heightened scrutiny on real-world effectiveness and safety monitoring, prompting sponsors to design integrated evidence generation strategies that extend beyond randomized controlled trials.

At the same time, payers and health technology assessors are experimenting with outcome-based reimbursement models and coverage with evidence development, which reshapes commercial planning and patient access strategies. Manufacturers must therefore craft value dossiers that demonstrate not only biomarker modulation but meaningful cognitive and functional outcomes across clinically relevant time horizons. Moreover, diagnostic advancement, particularly in imaging and fluid biomarkers, is changing referral patterns and enabling earlier intervention, which in turn impacts trial design, patient recruitment, and long-term care models. Taken together, these shifts demand agile clinical programs, adaptive regulatory engagement, and proactive payer dialogue to secure sustainable adoption of anti-amyloid therapeutics.

Assessing how 2025 United States tariff measures could reshape supply chain resiliency, manufacturing economics, and payer dynamics across the anti-amyloid therapy ecosystem

United States tariff actions in 2025 introduce another layer of complexity for anti-amyloid therapy stakeholders by altering the economics and logistics of global pharmaceutical supply chains. Tariffs can increase costs for active pharmaceutical ingredients, biologics components, specialized reagents, and certain finished products that traverse international manufacturing networks, prompting manufacturers to reassess sourcing strategies and inventory policies. In response, many organizations will accelerate supplier diversification, nearshore manufacturing investments, and strategic inventory buffering to mitigate exposure to tariff volatility and to sustain uninterrupted clinical trial supply and commercial distribution.

Tariff-driven cost pressures also have implications for contract manufacturing organizations and service providers that support biologics and peptide synthesis, potentially compressing margins and forcing repricing negotiations. Payers and hospital procurement teams may face higher acquisition costs for therapies, which could influence formulary decisions and prior authorization requirements. From a research perspective, increased import costs for specialized lab materials could slow some discovery programs or shift early-stage work toward domestic hubs and academic partnerships. Overall, tariffs amplify the need for scenario planning, contract flexibility, and enhanced coordination across procurement, regulatory, and commercial teams to preserve access and maintain investment in long-term clinical programs.

Deep segmentation-driven insights revealing how therapy classes, indications, administration routes, care settings, distribution channels, mechanisms, and age cohorts influence strategy

Disaggregating the market through distinct segmentation lenses reveals nuanced pathways to clinical and commercial differentiation that stakeholders can exploit. Based on therapy type, the competitive field includes monoclonal antibodies, peptides, and small molecules, with monoclonal antibodies further differentiated into chimeric, fully human, and humanized constructs; each class carries unique manufacturing demands, immunogenicity profiles, and regulatory expectations that influence development timelines and commercialization strategies. Based on indication, clinical strategy varies between Alzheimer's disease mild-to-moderate and Alzheimer's disease severe, with the mild-to-moderate category further subdivided into mild and moderate disease states; these indication nuances determine trial endpoints, patient selection criteria, and post-approval evidence commitments.

Based on route of administration, delivery modality analysis must consider intravenous, oral, and subcutaneous options, because administration route affects patient adherence, site-of-care economics, and cold-chain requirements. Based on end user, utilization patterns differ across home care, hospitals, specialty clinics, and telehealth services, with hospitals further distinguished as private and public institutions; these distinctions matter for distribution logistics, payer negotiations, and real-world monitoring. Based on distribution channel, the pathways include direct-to-patient distribution, hospital pharmacies, online pharmacies, and retail pharmacies, and hospital pharmacies can be divided into inpatient and outpatient settings; channel selection impacts patient access, reimbursement flow, and patient support program design. Based on mechanism of action, therapeutic strategies range from beta amyloid aggregation inhibition, beta amyloid clearance, beta amyloid production reduction, to neuroinflammation modulation, and each mechanism implies different biomarker strategies and safety surveillance needs. Finally, based on patient age group, clinical and commercial approaches must address cohorts of 65 to 74 years, 75 years and above, and below 65 years, since age stratification influences risk profile, comorbidity management, and health-system engagement. Synthesizing these segmentation lenses enables stakeholders to prioritize investments in development pathways, manufacturing capacity, diagnostic partnerships, and patient support infrastructures that align with targeted clinical benefits and payer expectations.

Regional strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine regulatory approach, access pathways, and commercialization tactics

Regional dynamics exert a decisive influence on regulatory pathways, reimbursement environments, and commercial roll-out strategies, with distinct implications across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory precedent and payer negotiation mechanisms tend to favor robust evidence packages and value-based contracting pilots, which drives manufacturers to invest in real-world evidence and phased rollout strategies aligned with major health systems. Meanwhile, infrastructure for advanced diagnostics in some parts of the region accelerates patient identification, but access disparities require complementary patient support and hub-and-spoke distribution models to reach non-urban populations.

In Europe, Middle East & Africa, regulatory diversity and heterogeneous reimbursement frameworks demand localized market access strategies, partnerships with regional distributors, and adaptive pricing approaches. Several jurisdictions emphasize health technology assessments and long-term outcome data, which incentivizes manufacturers to build registries and conditional reimbursement arrangements. In the Asia-Pacific region, growing investment in biotech manufacturing capacity and expanding diagnostic capabilities create opportunities for rapid clinical scale-up, but stakeholders must navigate variable regulatory timelines, local clinical practice patterns, and diverse payer landscapes. Across all regions, strategic collaboration with local clinical champions, payers, and diagnostics providers expedites adoption while mitigating geopolitical and tariff-induced supply risks.

Competitive and partnership strategies among biopharma innovators, biotechnology entrants, CDMOs, and diagnostics partners that shape product differentiation and commercialization success

Key companies operating in the anti-amyloid domain are differentiating through specialized pipelines, strategic collaborations, and investments in upstream diagnostics and downstream patient support. Biopharmaceutical leaders focus on platform capabilities in antibody engineering and scalable biologics manufacturing, while smaller biotechnology firms often pursue niche mechanisms of action or innovative delivery platforms to carve differentiated clinical value. Contract development and manufacturing organizations play a pivotal role in enabling scalable production for complex biologics and peptides, and their capacity constraints or expansions materially affect sponsor strategy and launch timing.

Strategic partnerships between therapeutic developers and diagnostic companies are increasingly central, as reliable biomarker-driven patient identification underpins payer acceptance and efficient clinical trial enrollment. Additionally, alliances with specialty pharmacies and in-home care providers reinforce continuity of care and adherence, especially for therapies requiring ongoing administration or monitoring. Payer engagement strategies vary by company, from early HTA dialogues to pilot outcomes agreements, and successful organizations pair clinical evidence generation with pragmatic reimbursement pilots to demonstrate value in routine care. Collectively, these corporate strategies reflect a broader industry trend toward integrated, evidence-informed commercialization that aligns R&D investment with downstream access imperatives.

Actionable strategic recommendations for leaders to align R&D, manufacturing resilience, diagnostic partnerships, pricing innovation, and patient-centric access programs

Industry leaders should adopt a coordinated set of strategic actions to capture clinical, regulatory, and commercial advantage in the anti-amyloid space. First, align development programs with downstream evidence needs by integrating real-world data collection and patient-reported outcomes into pivotal and post-approval studies to address regulator and payer questions concurrently. Second, diversify manufacturing and procurement footprints to reduce exposure to geopolitical and tariff disruptions; consider nearshoring critical components and negotiating flexible supplier agreements to maintain supply continuity. Third, invest in diagnostic partnerships and clinician education to accelerate accurate patient identification and appropriate use, which will support payer discussions and enhance uptake.

Fourth, design flexible pricing and reimbursement strategies, including outcome-based arrangements and staged access models, to share risk with payers while building a robust evidentiary base. Fifth, develop patient-centric delivery and support programs that optimize adherence, monitor safety, and reduce treatment abandonment-these programs should integrate telehealth touchpoints and home-based services where clinically appropriate. Finally, foster cross-functional collaboration between R&D, regulatory, manufacturing, and commercial teams to ensure launch readiness is synchronized with supply capacity, clinician training, and payer engagement plans. Executing these priorities will improve the likelihood of sustained access and meaningful patient benefit.

A robust mixed-method research methodology combining stakeholder interviews, secondary evidence synthesis, triangulation, and validation to ensure credible and actionable insights

This research employed a mixed-methods approach to generate rigorous, actionable insights that combine qualitative stakeholder perspectives with structured evidence synthesis. Primary research comprised in-depth interviews with clinical investigators, health system leaders, regulatory affairs specialists, payer representatives, and manufacturing experts, capturing firsthand perspectives on clinical endpoints, trial feasibility, reimbursement considerations, and supply chain constraints. Complementing these interviews, secondary evidence synthesis reviewed peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to map scientific progress, safety considerations, and regulatory posture.

Data triangulation validated thematic findings across sources and supported scenario analysis on supply chain and market access sensitivities. Segmentation mapping linked clinical development strategies to likely commercialization pathways, while thematic coding of qualitative interviews identified persistent barriers and successful mitigation strategies. The methodology incorporated stakeholder validation sessions to refine conclusions and ensure practical relevance for decision-makers. Limitations include the evolving regulatory environment and rapid scientific progress that may introduce new evidence after data collection; to mitigate this, the research applied conservative interpretation of emergent data and highlighted areas for ongoing monitoring. Ethical standards and confidentiality protocols governed all primary interactions and data handling.

Concluding synthesis underscoring momentum, multifaceted challenges, and strategic priorities required to translate anti-amyloid innovation into sustained patient access

In synthesis, the anti-amyloid therapy landscape presents a rare conjunction of scientific promise and systemic complexity that requires integrated, evidence-driven strategies. Therapeutic innovation across monoclonal antibodies, peptides, and small molecules offers diversified pathways to affect disease biology, yet each approach carries distinct manufacturing, clinical, and reimbursement challenges. Regulatory and payer environments are evolving in parallel, increasingly demanding real-world evidence and demonstrable functional outcomes, which necessitates proactive planning for post-approval studies and creative contracting models.

Stakeholders that succeed will be those that anticipate intersectional risks-manufacturing constraints, tariff impacts, diagnostic bottlenecks, and heterogeneous regional requirements-and that translate those anticipations into operational actions. Strategic alignment across development, manufacturing, diagnostics, and market access functions will reduce time-to-uptake and enhance patient reach. Ultimately, the field's momentum can translate into meaningful patient benefit if organizations commit to cross-disciplinary collaboration, adaptive evidence generation, and resilient commercialization execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-amyloid Therapy Market, by Therapy Type

  • 8.1. Monoclonal Antibodies
    • 8.1.1. Chimeric Monoclonal Antibodies
    • 8.1.2. Fully Human Monoclonal Antibodies
    • 8.1.3. Humanized Monoclonal Antibodies
  • 8.2. Peptides
  • 8.3. Small Molecules

9. Anti-amyloid Therapy Market, by Indication

  • 9.1. Alzheimer's Disease Mild-To-Moderate
    • 9.1.1. Mild Alzheimer's Disease
    • 9.1.2. Moderate Alzheimer's Disease
  • 9.2. Alzheimer's Disease Severe

10. Anti-amyloid Therapy Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Anti-amyloid Therapy Market, by Mechanism Of Action

  • 11.1. Beta Amyloid Aggregation Inhibition
  • 11.2. Beta Amyloid Clearance
  • 11.3. Beta Amyloid Production Reduction
  • 11.4. Neuroinflammation Modulation

12. Anti-amyloid Therapy Market, by Patient Age Group

  • 12.1. 65 To 74 Years
  • 12.2. 75 Years And Above
  • 12.3. Below 65 Years

13. Anti-amyloid Therapy Market, by End User

  • 13.1. Home Care
  • 13.2. Hospitals
    • 13.2.1. Private Hospitals
    • 13.2.2. Public Hospitals
  • 13.3. Specialty Clinics
  • 13.4. Telehealth Services

14. Anti-amyloid Therapy Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Anti-amyloid Therapy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Anti-amyloid Therapy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Anti-amyloid Therapy Market

18. China Anti-amyloid Therapy Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Biogen Inc.
  • 19.9. Bristol Myers Squibb Company
  • 19.10. Eisai Co. Ltd.
  • 19.11. Eli Lilly and Company
  • 19.12. Gilead Sciences Inc.
  • 19.13. GlaxoSmithKline plc
  • 19.14. Johnson & Johnson
  • 19.15. Merck & Co. Inc.
  • 19.16. Novartis AG
  • 19.17. Pfizer Inc.
  • 19.18. Roche Holding AG
  • 19.19. Sanofi S.A.
  • 19.20. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-AMYLOID THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-AMYLOID THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY CHIMERIC MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY CHIMERIC MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY CHIMERIC MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY FULLY HUMAN MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY FULLY HUMAN MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY FULLY HUMAN MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HUMANIZED MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HUMANIZED MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HUMANIZED MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MILD ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MILD ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MILD ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MODERATE ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MODERATE ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MODERATE ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID AGGREGATION INHIBITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID AGGREGATION INHIBITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID AGGREGATION INHIBITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID CLEARANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID CLEARANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID CLEARANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID PRODUCTION REDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID PRODUCTION REDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID PRODUCTION REDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY NEUROINFLAMMATION MODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY NEUROINFLAMMATION MODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY NEUROINFLAMMATION MODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY 65 TO 74 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY 65 TO 74 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY 65 TO 74 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY 75 YEARS AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY 75 YEARS AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY 75 YEARS AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BELOW 65 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BELOW 65 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BELOW 65 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY TELEHEALTH SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY TELEHEALTH SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY TELEHEALTH SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)